Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Papillomavirus Infections

ClinicalTrials.gov lists 748 trials for Papillomavirus Infections or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 71.

MeSH D030361 Infections C01 C12 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 40 Phase 1/2 Phase 1/2 17 Phase 2 Phase 2 108 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 136 Phase 4 Phase 4 47 Not applicable Not applicable 206 Observational Observational 182 Phase 1 Phase 1 40 Phase 1/2 Phase 1/2 17 Phase 2 Phase 2 108 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 136 Phase 4 Phase 4 47 Not applicable Not applicable 206 Observational Observational 182

Trials per phase

561 of the 748 trials are tagged with Papillomavirus Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Papillomavirus Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Papillomavirus Infections trials start? (29)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 63

1994: 1 trials (Observational 1) 1999: 1 trials (Phase 2 1) 2000: 2 trials (Phase 2 2) 2001: 5 trials (Observational 1, Phase 3 2, Phase 2 2) 2002: 5 trials (Observational 1, Phase 4 1, Phase 3 3) 2003: 7 trials (Observational 1, Phase 3 4, Phase 2 2) 2004: 12 trials (Not applicable 1, Phase 3 6, Phase 2 5) 2005: 12 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 4, Phase 2 4) 2006: 19 trials (Observational 4, Phase 4 1, Phase 3 5, Phase 2 8, Phase 1 1) 2007: 39 trials (Observational 9, Not applicable 5, Phase 4 1, Phase 3 13, Phase 2 5, Phase 1 6) 2008: 23 trials (Observational 8, Not applicable 1, Phase 3 8, Phase 2 3, Phase 1 3) 2009: 31 trials (Observational 11, Not applicable 4, Phase 4 3, Phase 3 12, Phase 1 1) 2010: 33 trials (Observational 17, Not applicable 4, Phase 4 5, Phase 3 3, Phase 2/3 2, Phase 2 1, Phase 1/2 1) 2011: 28 trials (Observational 7, Not applicable 4, Phase 4 2, Phase 3 11, Phase 2/3 1, Phase 2 1, Phase 1 2) 2012: 28 trials (Observational 10, Not applicable 8, Phase 3 3, Phase 2 4, Phase 1/2 2, Phase 1 1) 2013: 12 trials (Observational 2, Not applicable 5, Phase 3 2, Phase 2/3 1, Phase 2 2) 2014: 16 trials (Observational 3, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2/3 2, Phase 2 4, Phase 1 1) 2015: 26 trials (Observational 5, Not applicable 5, Phase 4 1, Phase 3 3, Phase 2 11, Phase 1 1) 2016: 21 trials (Observational 2, Not applicable 8, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 2) 2017: 24 trials (Observational 4, Not applicable 5, Phase 4 2, Phase 3 3, Phase 2 6, Phase 1/2 1, Phase 1 3) 2018: 28 trials (Observational 5, Not applicable 10, Phase 4 2, Phase 3 5, Phase 2 3, Phase 1/2 1, Phase 1 2) 2019: 33 trials (Observational 6, Not applicable 13, Phase 3 4, Phase 2 4, Phase 1 6) 2020: 47 trials (Observational 11, Not applicable 12, Phase 4 7, Phase 3 9, Phase 2/3 1, Phase 2 6, Phase 1 1) 2021: 38 trials (Observational 12, Not applicable 10, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 1, Phase 1/2 2) 2022: 63 trials (Observational 17, Not applicable 23, Phase 4 7, Phase 3 9, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 3) 2023: 52 trials (Observational 17, Not applicable 16, Phase 4 4, Phase 3 4, Phase 2 7, Phase 1/2 1, Phase 1 3) 2024: 49 trials (Observational 15, Not applicable 24, Phase 4 1, Phase 3 1, Phase 2/3 2, Phase 2 3, Phase 1/2 2, Phase 1 1) 2025: 43 trials (Observational 10, Not applicable 20, Phase 4 2, Phase 3 6, Phase 2 4, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 44
2025 43
2024 49
2023 52
2022 63
2021 38
2020 47
2019 33
2018 28
2017 24

Showing 10 of 29 earlier years.

Start your 14-day trial Email me all 29 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 54 trials starting in 2026 and about 47 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 80 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 458 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Papillomavirus Infections trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 40
Phase 1/2 17
Phase 2 108
Phase 2/3 12
Phase 3 136
Phase 4 47
Not applicable 206
Observational 182

How many Papillomavirus Infections trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 44
Recruiting 75
Enrolling by invitation 5
Active, not recruiting 55
Completed 415

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Papillomavirus Infections trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 71
Merck Sharp & Dohme LLC 50
National Cancer Institute (NCI) 20
Shanghai Bovax Biotechnology Co., Ltd. 13
AIDS Malignancy Consortium 8

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Papillomavirus Infections? (1)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Resiquimod 6

Interventions as named in the registry (14)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cervarix TM 31
Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®) 14
V503 12
CRYOTHERAPY 11
GARDASIL 11

Showing 5 of 14 interventions.

Start your 14-day trial Email me all 14 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Papillomavirus Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Abortion spontaneous 319 19
Appendicitis 277 42
Abortion induced 168 12
Abortion spontaneous incomplete 167 14
Abortion spontaneous complete 156 16

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Papillomavirus Infections? (1,768)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Effect of Prior 9-Valent Human Papillomavirus Vaccination on Subsequent Lower Genital Tract Dysplasia After Cervical Excisional Surgery. Obstetrics and gynecology 2026 Yes
Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection. Journal of the National Cancer Institute 2026 Yes
Promoting cervical cancer screening via a mailed HPV self-collection kit: Reactions from screeners and non-screeners. Patient education and counseling 2026 Yes
Underscreened Women's Reactions to At-Home Self-Collected Human Papillomavirus Test Result Delivery. Sexually transmitted diseases 2026 Yes
Process evaluation of a school-based vaccination intervention to improve HPV vaccine coverage: A mixed-method study embedded in the French PrevHPV cluster randomized controlled trial. Vaccine 2026 Yes

Showing 5 of 1,768 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages